AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 292 min read$CYTK

Lee Sung sold $3.2M of CYTK

Lee Sung (EVP, Chief Financial Officer) sold 38,730 shares of CYTOKINETICS INC (CYTK) at $82.30 ($3.19M total) on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lee Sung
Published Jun 29, 2026, 10:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

Confirms a CFO open-market sale executed under a pre-arranged 10b5-1 plan; typically lower informational content than unscheduled selling.

02

Market read

Useful for tracking insider behavior, but unlikely to drive a fundamental repricing by itself.

03

What to watch

Traders should check whether the sale size is unusual relative to prior Form 4 activity and whether there are concurrent insider buys or new company disclosures.

Relevance 5/10Novelty 5/10Timing: new Form 4 filed 2026-06-29 (sale executed 2026-06-24)

Background

The article is a SEC Form 4 insider transaction disclosure for Cytokinetics, Inc.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CYTOK insider Lee Sung (CFO) sold 38,730 shares in an open-market transaction at $82.30 on 2026-06-24 under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any effect is short-lived unless paired with other fundamental news.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan; while it confirms selling activity, it does not disclose new operating or financial information.

Market effects

Sector

No clear sector read-through; this is company-specific insider liquidity activity.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    Company whose CFO insider transaction is disclosed on Form 4.

  • insider
    Lee Sung

    EVP, Chief Financial Officer; reported open-market sale of CYTK shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 6
$CYTKMedAI 8/10

CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Sup

SEC EDGAR 8-K6 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics Secures MHRA Marketing Authorization For MYQORZO In OHCM

Cytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).

rttnews.com4 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics' cardiomyopathy drug cleared for NHS use

Cytokinetics said the UK MHRA and NICE cleared its cardiomyopathy drug Myqorzo (aficamten) for NHS use as an add-on to standard therapy in adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. NICE required cost parity with Bristol Myers Squibb’s Camzyos. Myqorzo made about $5m in Q1 sales; Camzyos $314m.

pharmaphorum.com4 min
JUL 24
$CYTKMed

What Makes Cytokinetics' MYQORZO Launch a Game Changer

Cytokinetics (CYTK) is commercializing MYQORZO (aficamten), approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China. The U.S. launch began in January 2026 and Europe is planned for Germany in Q2 2026. In 2025, revenue rose to $88.0M and net loss widened to $784.9M, while cash was about $1.22B.

kavout.com6 min
JUN 1
$CYTKMedAI 8/10

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics (Nasdaq: CYTK) said MYQORZO® (aficamten) has launched commercially in Germany, the first European availability, for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA II–III). The company cited EU approval in February 2026 based on SEQUOIA-HCM Phase 3 results, including a 1.76 mL/kg/min pVO2 improvement vs 0.0 with placebo over 24 weeks.

manilatimes.net4 min